Academic history
Robert Chen, MD, is the Global Head of Lymphoma Clinical Development and Strategy at AstraZeneca. Formerly, Prof. Chen was an Associate Professor of Medicine and Associate Director at the Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA.
Prof. Chen completed his medical studies at the Northwestern University Feinberg School of Medicine, Chicago, IL. He then completed his residency in internal medicine at the University of Colorado Health Sciences Center, Denver, CO, followed by his hematology/oncology fellowship at the University of Colorado Cancer Center, Aurora, CO.
Prof. Chen is a member of various societies, namely the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, and the Rocky Mountain Oncology Society (Colorado).
Speaking on malignant hematology, chemotherapy and stem cell transplantation
Prof. Chen’s research interests lie in malignant hematology and its therapies, particularly chemotherapy and stem cell transplantation. He has extensively been involved in clinical trials assessing efficacy of novel agents such as the CD47 blocker TTI-621 and ibrutinib in patients with relapsed/refractory hematologic malignancies.
